{"id":"cosopt-pf-2-0-5-ophthalmic-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular burning or stinging"},{"rate":null,"effect":"Blurred vision"},{"rate":null,"effect":"Tearing"},{"rate":null,"effect":"Corneal erosion"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2108251","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dorzolamide inhibits carbonic anhydrase in the ciliary body, reducing aqueous humor secretion. Timolol is a non-selective beta-adrenergic antagonist that further decreases aqueous humor production and may increase uveoscleral outflow. Together, these dual mechanisms provide additive intraocular pressure reduction in glaucoma and ocular hypertension.","oneSentence":"Cosopt PF combines a topical carbonic anhydrase inhibitor (dorzolamide) and a beta-blocker (timolol) to reduce intraocular pressure through decreased aqueous humor production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:43:55.041Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT06883123","phase":"PHASE4","title":"Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost","status":"RECRUITING","sponsor":"Prairie Eye Center","startDate":"2025-05-14","conditions":"Open Angle Glaucoma","enrollment":70},{"nctId":"NCT04702789","phase":"PHASE4","title":"Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension.","status":"TERMINATED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2021-10-19","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Cosopt PF 2%-0.5% Ophthalmic Solution","genericName":"Cosopt PF 2%-0.5% Ophthalmic Solution","companyName":"Prairie Eye Center","companyId":"prairie-eye-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cosopt PF combines a topical carbonic anhydrase inhibitor (dorzolamide) and a beta-blocker (timolol) to reduce intraocular pressure through decreased aqueous humor production. Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}